Skip to main content
AMGN logo

AMGN · Amgen Inc

Track AMGN — free
$438.92 +5.19 (+1.20%)
Market Cap
$234.49B
Shares
540.63M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$433.73 Open$435.78 Day$431.07–441.34 52W close$271.18–442.36 Avg vol 30d2.6M Short int13.3M · 2.5% float · 5.2d Short vol62% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +23%
      above
      Price vs 50-day avg +15%
      above
      RSI (14) 72
      overbought
      MACD trend Positive
      52-week position 95%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +17%
      trailing
      6-month return +12%
      trailing
      YTD return +33%
      this year
      Relative strength +1%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $377 › 200d $352 — 50d above 200d
      Institutional flow Distributing
      -0% holders QoQ · +177 funds added
      Insider flow Distributing
      Net -$4.1M over 90 days · 100% sells
      Short interest Rising
      2.46% of float · ▲ +3.4% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      3,151 holders — near 3-yr high, broad support
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +9%
      Y/Y
      EPS growth +88%
      Y/Y
      Free cash flow $8.1B
      Valuation P/E 27
      below peers
      Buyback $6.8B
      remaining
      Balance sheet $45.3B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 28%
      annualized · 1-yr
      Max drawdown −17%
      past year
      ATR 2.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Aug 4, 2026
      Total revenues · full year 2026 Initiated $38.2B – $39.4B
      prior FY $36.75B midpoint +5.6% Y/Y
      EPS · full year 2026 Initiated $15.80 – $17.08
      prior FY $14.23 midpoint +15.5% Y/Y
      EPS · full year 2026 Initiated $22.30 – $23.50
      Tax rate · full year 2026 Initiated 14.5% – 16%
      Tax rate · full year 2026 Initiated 15% – 16.5%
      Capital expenditures · full year 2026 Initiated $2.6B
      Share repurchases · full year 2026 Initiated up to $3B
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Total revenues · full year 2025 $35.8B – $36.6B
      EPS · full year 2025 $13.76 – $14.60
      Tax rate · full year 2025 14.5% – 16%
      Tax rate · full year 2025 15% – 16.5%
      EPS · full year 2025 $20.60 – $21.40
      Guided vs delivered · last 3 settled
      Total revenues full year 2025
      guided $35.8B – $36.6B
      $36.75B Beat +1.5%
      EPS full year 2025
      guided $13.76 – $14.60
      $14.23 In line
      Revenue full-year 2023
      guided $28B – $28.4B
      $28.19B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +23% Bullish
      Price vs 50-day avg
      +15% Bullish
      RSI (14)
      72 Bearish
      MACD trend
      Positive Bullish
      52-week position
      95% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $377 › 200d $352 — 50d above 200d
      Institutional flow Distributing
      -0% holders QoQ · +177 funds added
      Insider flow Distributing
      Net -$4.1M over 90 days · 100% sells
      Short interest Rising
      2.46% of float · ▲ +3.4% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      3,151 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $271 Now $434 · 95% Range high $442
      vs 200-day avg +23% vs 50-day avg +15%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Capital Expenditures 0.5B Q2 ’26
      Debt leverage ratio non-GAAP 3.2 as of December 31, 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - General — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AMGN
      Amgen Inc
      this stock
      $234.49B +32.5% +8.8% 27.0 2.5%
      LLY
      ELI LILLY & Co
      $1.21T +15.8% +44.7% 43.0 1.0%
      JNJ
      Johnson & Johnson
      $658.89B +29.2% +6.0% 31.8 1.1%
      ABBV
      AbbVie Inc.
      $462.68B +14.6% +8.6% 74.0 1.3%
      MRK
      Merck & Co., Inc.
      $375.50B +41.5% +1.3% 121.8 1.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      3,151
      % held
      84.4%
      Net QoQ
      +19.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,194
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      13.3M
      Days to cover
      5.2d
      Change
      +435.6K sh
      View
      Short Volume
      Short vol %
      62%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.3K
      Value
      $907.1K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      39.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$4.1M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      David J. Taylor
      Amount
      $1.0K–$15.0K
      Traded
      Jun 5, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $36.8B
      Net income (FY)
      $7.7B
      EPS diluted
      $14.23
      View
      Buybacks
      Remaining
      $6.8B
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 5, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $516.8K
      Shares
      1.3K
      Filed
      Aug 13, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 6, 2026
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      AMGN +3.8% +16.8% +11.7% +12.6% +32.5%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +5.8% +13.4% +0.6% +10.5% +20.7%

      Capital returns

      Latest dividend
      $2.52 / share · ex Aug 21, 2026
      Raised 5.9%
      Paid (TTM)
      $12.32 / share · 5 payouts
      Dividend yield (TTM, derived)
      2.84%
      Buyback program · as of Jun 30, 2026
      Authorized
      Spent (derived)
      Remaining
      $6.80B

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 318154 CUSIP 031162100 13F (30d) 2480 filings 2409 filers Visit website Investor relations